Skip to main content
. 2022 Mar 14;12:101. doi: 10.1038/s41398-022-01847-8

Table 1.

Demographic characteristics in the GAPP-MDD clinical trial at baseline by treatment in the per-protocol cohort.

Demographics Treatment Total (N = 276) p-value
TAU (N = 93) GEN (N = 90) E-GEN (N = 93)
Age group, n (%)
18 to 34 35 (37.6) 42 (46.7) 32 (34.4) 109 (39.5) 0.21
35 to 49 27 (29.0) 21 (23.3) 32 (34.4) 80 (29.0) 0.26
50 to 64 25 (26.9) 20 (22.2) 25 (26.9) 70 (25.4) 0.71
65 and over 6 (6.5) 7 (7.8) 4 (4.3) 17 (6.2) 0.61
Age
Mean (SD) 42.3 (14.2) 40.3 (15.3) 40.7 (12.9) 41.1 (14.1) 0.62
Min, Max 20.0, 78.0 19.0, 76.0 18.0, 69.0 18.0, 78.0
Gender, n (%)
Female 59 (63.4) 59 (65.6) 60 (64.5) 178 (64.5) 0.96
Male 34 (36.6) 31 (34.4) 33 (35.5) 98 (35.5) 0.96
Ethnicity, n (%)a
Asian 7 (7.5) 10 (11.1) 7 (7.5) 24 (8.7) 0.61
Black 1 (1.1) 3 (3.3) 4 (4.3) 8 (2.9) 0.40
Caucasian 83 (89.2) 72 (80.0) 77 (82.8) 232 (84.1) 0.21
Latin American 2 (2.2) 2 (2.2) 1 (1.1) 5 (1.8) 0.81
Other 0 3 (3.3) 4 (4.3) 7 (2.5) 0.15
Depression category, n (%)
Moderate (HAM-D17 14–18) 28 (30.1) 26 (28.9) 30 (32.3) 84 (30.4) 0.88
Severe (HAM-D17 19–22) 25 (26.9) 24 (26.7) 27 (29.0) 76 (27.5) 0.92
Very severe (HAM-D17 > 22) 40 (43.0) 40 (44.4) 36 (38.7) 116 (42.0) 0.71
Psychiatric comorbidities, n (%)
Generalized anxiety disorder 35 (37.6) 45 (50.0) 38 (40.9) 119 (43.1) 0.23
Panic disorder 8 (8.6) 15 (16.7) 15 (16.1) 38 (13.8) 0.21
Post-traumatic stress disorder 7 (7.5) 7 (7.8) 8 (8.6) 22 (8.0) 0.96
HAM-D17
Mean (SD) 21.4 (4.5) 21.3 (4.7) 21.5 (4.8) 21.4 (4.7) 0.99
Min, Max 14.0, 36.0 14.0, 36.0 14.0, 33.0 14.0, 36.0
Number of failed psych meds, n
1 28 14 20 62 0.0598
2 20 23 15 58 0.29
3 12 8 14 34 0.44
4 9 17 8 34 0.07
5 8 7 10 25 0.77
6+ 13 20 24 57 0.12
Missingb 3 1 2 6 0.62
Mean (SD) 3.0 (2.2) 3.7 (2.2) 4.0 (3.1) 3.6 (2.6) 0.0388
Min, Max 1.0, 9.0 1.0, 8.0 1.0, 21.0 1.0, 21.0

aExpanded ethnicity groupings are presented in Supplementary Tables 1012.

bPatient who reported failing ≥1 prior medication trial, but did not report specific number of prior failed trials.